Related Experiment Video
Updated: May 18, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
New agents for the treatment of lymphoma
1Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. anastasios.stathis@eoc.ch
Abstract:
Despite improvements in the diagnosis and management of lymphomas, many patients remain incurable with available treatments. advances in preclinical research and a better understanding of the molecular biology of lymphomas have allowed the development of a high number of therapeutic agents with innovative mechanisms of action. Many of these new agents have shown activity in patients not responding to standard treatments and there is optimism that their incorporation into the standard of care can result in improved treatment outcomes. Here we review new monoclonal antibodies and small molecules that have recently entered clinical evaluation for patients with lymphomas.
Insights
New therapeutic agents, including monoclonal antibodies and small molecules, show promise for treating lymphomas, offering hope for patients resistant to current therapies.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Lymphomas remain challenging to cure despite diagnostic and management advances.
- Preclinical research and molecular biology insights drive new therapeutic development.
Framework:
- Review of novel monoclonal antibodies and small molecules in clinical evaluation.
- Focus on agents with innovative mechanisms of action.
Implementation:
- New agents demonstrate activity in patients refractory to standard lymphoma treatments.
- Clinical evaluation is underway for these promising therapeutic options.
Implications:
- Incorporation of novel agents into standard care may improve lymphoma treatment outcomes.
- Offers new hope for incurable lymphoma patients and advances lymphoma therapy.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Lymphoid Cells and Tissues
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...

